Last updated: July 31, 2026
Zaroxolyn is the branded formulation of metolazone, an oral thiazide-like diuretic used primarily for edema associated with congestive heart failure, renal disease and hypertension. Its commercial position is mature and genericized. The FDA-approved product has no meaningful remaining market exclusivity, no active branded innovation program and limited drug-specific clinical-trial activity. Future demand should remain stable to modestly declining, with use concentrated in chronic heart failure, resistant fluid overload and combination therapy with loop diuretics.
What is Zaroxolyn and how is metolazone used?
Zaroxolyn contains metolazone, a quinazoline-derived thiazide-like diuretic. It inhibits sodium and chloride reabsorption in the distal renal tubule and remains active in patients with reduced renal function, where conventional thiazide diuretics may have less effect.
The U.S. product has historically been marketed in 2.5 mg, 5 mg and 10 mg tablets. Clinical use generally involves low-dose oral administration, often alongside furosemide, torsemide or bumetanide when loop-diuretic therapy alone does not control congestion.
The FDA labeling identifies the main indications as:
- Edema associated with congestive heart failure.
- Edema associated with renal disease, including nephrotic syndrome and impaired renal function.
- Hypertension, either alone or in combination with other antihypertensive agents.
Metolazone has a narrow practical safety margin in volume-depleted patients. Clinically important risks include hyponatremia, hypokalemia, hypomagnesemia, dehydration, hypotension, hyperuricemia and renal-function deterioration. Electrolyte monitoring is central to treatment, particularly when metolazone is combined with a loop diuretic (DailyMed, 2024).
What is the FDA regulatory status of Zaroxolyn?
Zaroxolyn is an FDA-approved legacy drug with generic competition. The product is associated with an older New Drug Application, and metolazone tablets are available from multiple generic manufacturers through abbreviated new drug applications.
FDA approval and dosage forms
| Attribute |
Status |
| Active ingredient |
Metolazone |
| Brand |
Zaroxolyn |
| Drug class |
Thiazide-like diuretic |
| Route |
Oral |
| U.S. dosage form |
Immediate-release tablet |
| Common strengths |
2.5 mg, 5 mg, 10 mg |
| FDA pathway |
Original NDA followed by generic ANDA approvals |
| Current exclusivity |
None expected |
| Biosimilar pathway |
Not applicable |
| Primary commercial market |
Generic prescription market |
The branded Zaroxolyn product has had limited commercial visibility relative to generic metolazone. Availability can vary by strength, manufacturer and wholesaler inventory. A product listed in the FDA Orange Book does not necessarily indicate that the original brand remains widely distributed or commercially promoted (U.S. Food and Drug Administration, 2024a).
What patents protect Zaroxolyn and metolazone?
No commercially significant active patent estate is generally associated with the original Zaroxolyn product. The core metolazone composition, conventional tablet formulation and principal therapeutic uses date to the 1960s and 1970s. Those rights would have expired decades ago.
Patent and exclusivity position
| IP category |
Current assessment |
| Core compound patent |
Expired |
| Original composition patent |
Expired |
| Conventional tablet formulation |
No meaningful current exclusivity |
| Method-of-use protection |
Historical rights expired |
| Pediatric exclusivity |
None of commercial relevance |
| Orphan exclusivity |
None |
| Patent-term extension |
No current commercial effect |
| U.S. market barrier |
Generic competition |
| Manufacturing barrier |
Low to moderate, depending on supplier qualification |
The principal IP risk is therefore not patent infringement. The more relevant operational risks are active pharmaceutical ingredient sourcing, quality compliance, manufacturing discontinuances and short-term supply constraints.
Are formulation patents relevant to Zaroxolyn?
Conventional immediate-release metolazone tablets are not protected by a material, currently enforceable branded formulation estate. A company could seek new protection for a modified-release tablet, liquid formulation, fixed-dose combination or other delivery system, but that would require a new product strategy and would not restore exclusivity to standard generic metolazone.
Any future formulation patent would need to establish a defensible combination of formulation composition, manufacturing process and clinical or pharmacokinetic performance. Because metolazone is inexpensive and used at low doses, the commercial return may not justify extensive formulation development unless the product targets a clear adherence, dosing or inpatient-use problem.
Are there active clinical trials for Zaroxolyn?
There is no major late-stage clinical development program for branded Zaroxolyn. Metolazone continues to appear in clinical practice, observational research and heart-failure treatment protocols, but modern studies usually evaluate the drug as part of a diuretic strategy rather than as a standalone investigational product.
Clinical-trial activity
| Area |
Current position |
| Standalone Zaroxolyn registration trial |
No active program of commercial significance |
| Heart-failure congestion studies |
Metolazone may appear as background or rescue therapy |
| Chronic kidney disease |
Used clinically for edema and diuretic resistance |
| Hypertension |
Established use; limited development interest |
| Pediatric development |
No active branded program of significance |
| Combination therapy |
Clinical use with loop diuretics remains relevant |
| FDA label expansion |
No visible near-term expansion pathway |
Clinical evidence continues to support sequential nephron blockade, in which a thiazide-like diuretic is added to a loop diuretic for persistent congestion. The evidence base is largely clinical-practice evidence, retrospective studies and heart-failure treatment experience rather than new pivotal trials designed to support a Zaroxolyn label expansion.
The strongest demand driver is diuretic resistance in acute or chronic heart failure. In such cases, clinicians may use metolazone before or during hospitalization, but dosing is individualized because aggressive diuresis can cause electrolyte abnormalities and acute kidney injury.
How does metolazone compare with other diuretics?
Metolazone competes across several therapeutic categories rather than against one direct branded product.
| Drug or class |
Main advantage |
Main limitation |
Competitive relationship |
| Furosemide |
Low cost, broad use, strong clinical familiarity |
Variable oral absorption and resistance in advanced congestion |
Primary companion drug |
| Torsemide |
More predictable absorption and longer duration |
Higher cost than generic furosemide |
Alternative loop-diuretic strategy |
| Bumetanide |
Potent, useful when absorption is a concern |
Higher unit cost and dosing complexity |
Alternative loop diuretic |
| Hydrochlorothiazide |
Low cost and extensive use in hypertension |
Less useful in severe renal impairment |
Competes in mild edema and hypertension |
| Chlorthalidone |
Long duration and strong antihypertensive effect |
Electrolyte and metabolic adverse effects |
Hypertension competitor |
| Acetazolamide |
Proximal-tubule mechanism; inpatient congestion use |
Different indication profile and metabolic effects |
Emerging hospital alternative |
| Tolvaptan |
Addresses hyponatremia and water retention |
Expensive and restricted use |
Niche alternative |
| SGLT2 inhibitors |
Heart-failure and renal benefits with mild diuresis |
Not a direct substitute for rescue diuresis |
Adjacent therapy |
The key differentiator for metolazone is its ability to augment loop-diuretic therapy at low cost. Its disadvantages are monitoring requirements, unpredictable patient response and the risk of excessive volume or electrolyte loss.
What is the Orange Book status of Zaroxolyn?
The FDA Orange Book identifies approved drug products and certain patent and exclusivity information. For metolazone, the regulatory profile is that of an established immediate-release oral product with generic competition. No active branded patent listing is expected to prevent ANDA approval or generic launch for standard metolazone tablets.
Paragraph IV challenges and generic entry
Paragraph IV litigation is unlikely to be a material current issue for conventional Zaroxolyn tablets because:
- The underlying patents are historical.
- Generic metolazone products have been marketed for years.
- No significant remaining period of branded market exclusivity is apparent.
- The product is commercially mature and low value per prescription.
Generic manufacturers therefore face ordinary ANDA requirements, including pharmaceutical equivalence, bioequivalence, chemistry, manufacturing and controls review, facility inspection and post-approval compliance. The principal entry barriers are manufacturing economics and supply-chain reliability rather than patent disputes.
What patent litigation and settlement agreements affect Zaroxolyn?
No major current patent litigation or settlement agreement is associated with conventional Zaroxolyn or generic metolazone tablets. The absence of active patent litigation is consistent with the product's age, low price and established generic market.
A new litigation risk could arise only if a sponsor commercialized a differentiated metolazone product, such as:
- Extended-release metolazone.
- A liquid or orally disintegrating formulation.
- A fixed-dose loop-diuretic combination.
- A hospital-administered formulation.
- A formulation claiming improved pharmacokinetic consistency or reduced electrolyte toxicity.
Those products could generate new patent filings, but they would compete against inexpensive generic immediate-release metolazone and would need clear clinical or workflow advantages.
Which companies compete in the metolazone market?
The market is fragmented among generic manufacturers and contract suppliers. Company participation can change as manufacturers discontinue products, transfer approvals or adjust production based on profitability.
The competitive landscape includes:
- Generic tablet manufacturers holding ANDAs for metolazone.
- Specialty pharmaceutical companies distributing legacy cardiovascular products.
- Wholesalers and pharmacy suppliers sourcing from multiple manufacturers.
- Compounding pharmacies in limited circumstances, subject to applicable regulatory requirements.
The branded Zaroxolyn name has limited strategic value unless supported by reliable supply, physician recognition or a differentiated formulation. Generic substitution is the dominant commercial behavior.
What is the market size and revenue outlook for Zaroxolyn?
Public company filings generally do not isolate metolazone revenue. The market is too mature and fragmented for Zaroxolyn sales to be a major disclosed revenue category for most suppliers.
Revenue exposure
| Segment |
Outlook |
| Branded Zaroxolyn |
Small and structurally pressured |
| Generic metolazone tablets |
Stable low-value demand |
| Hospital use |
Sensitive to heart-failure admissions and formulary policy |
| Retail prescriptions |
Gradual decline or stability depending on generic supply |
| Specialty formulation opportunity |
Potentially higher margin, but unproven |
| Total market growth |
Low single-digit decline to low single-digit growth by scenario |
Demand is tied to the prevalence of heart failure, chronic kidney disease, hypertension and diuretic-resistant edema. The countervailing factor is therapeutic substitution. Clinicians increasingly use SGLT2 inhibitors, optimized loop diuretics, acetazolamide-based inpatient strategies and other heart-failure therapies. These products do not eliminate metolazone use but can reduce reliance on it in selected patients.
What is the 2025–2030 projection for Zaroxolyn?
The base case is a mature, stable-to-declining market with no material branded growth.
Scenario projection
| Scenario |
2025–2030 expectation |
Principal drivers |
| Base case |
Flat to modest decline |
Generic substitution, stable heart-failure demand, limited innovation |
| Upside case |
Low single-digit growth |
More heart-failure admissions, increased recognition of sequential nephron blockade, supply stabilization |
| Downside case |
Moderate decline |
Greater use of alternative diuretic strategies, generic discontinuances, reduced branded availability |
A branded relaunch would require a differentiated value proposition. Brand promotion alone is unlikely to overcome generic pricing. The most credible commercial opportunity would involve a formulation that improves dosing convenience, reduces inpatient preparation or supports a validated clinical use case.
How strong is the Zaroxolyn patent estate?
The patent estate is weak for business-development and litigation purposes because the core product is long off-patent. The commercial value lies in manufacturing scale, distribution, supply continuity and potential product reformulation.
| Factor |
Assessment |
| Composition-of-matter protection |
Exhausted |
| Formulation protection |
Minimal for standard tablets |
| Regulatory exclusivity |
Exhausted |
| Generic threat |
High |
| Litigation leverage |
Low |
| Supply-chain leverage |
Moderate |
| Reformulation opportunity |
Possible but commercially uncertain |
| Investment profile |
Defensive, low-growth generic |
What generic entry risks exist for Zaroxolyn?
Generic entry is already established, so the relevant risk is erosion of the remaining branded share rather than a future first generic launch. Key risks include:
- Continued substitution from Zaroxolyn to metolazone.
- Price compression among ANDA holders.
- Manufacturer exits because of low margins.
- Shortages caused by API or finished-dose concentration.
- Pharmacy-level switching among generic suppliers.
- Reduced formulary preference for branded product.
- Clinical substitution with alternative diuretic regimens.
Manufacturing IP is not a major barrier. Regulatory compliance and consistent tablet quality are more important than patent ownership.
Key Takeaways
- Zaroxolyn is the branded metolazone product, an established oral thiazide-like diuretic.
- The product is off-patent and faces long-standing generic competition.
- No major active clinical-trial or branded lifecycle program is evident.
- Metolazone remains clinically relevant for diuretic resistance, especially with loop diuretics.
- The FDA regulatory profile is mature, with no meaningful remaining market exclusivity.
- Paragraph IV litigation, patent settlements and biosimilar risk are not material to the standard product.
- The 2025–2030 market outlook is stable to modestly declining.
- Any meaningful commercial upside would require a differentiated formulation or combination product.
FAQs about Zaroxolyn and metolazone
Does Zaroxolyn still have patent protection?
No commercially meaningful patent protection is expected for the original metolazone compound or conventional immediate-release Zaroxolyn tablets.
Is metolazone still used for heart failure?
Yes. It is used mainly as an adjunct to loop diuretics when congestion persists despite loop-diuretic therapy.
Can a generic company launch metolazone without a Paragraph IV dispute?
Yes. Standard metolazone tablets have long-established generic competition, and no significant current patent barrier is expected to block ordinary ANDA marketing.
Is Zaroxolyn a biologic or a biosimilar product?
No. Zaroxolyn is a small-molecule chemical drug. Biosimilar rules do not apply.
What could revive the Zaroxolyn brand?
A modified-release formulation, fixed-dose combination, liquid product or other formulation with demonstrated clinical and commercial advantages could create a new market opportunity. A simple branded relaunch would face strong generic substitution.
References
-
DailyMed. (2024). Zaroxolyn and metolazone prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
-
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., ... O'Connor, C. M. (2011). Diuretic strategies in patients with acute decompensated heart failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/NEJMoa1005419
-
U.S. Food and Drug Administration. (2024c). ClinicalTrials.gov database. National Library of Medicine. https://clinicaltrials.gov/
